Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind Study to Evaluate the Effect of Tarceva or Placebo Following Platinum-based CT on Overall Survival and Disease Progression in Patients With Advanced, Recurrent or Metastatic NSCLS Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy

NCT00556712 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00556712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00556712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind Study to Evaluate the Effect of Tarceva or Placebo Following Platinum-based CT on Overall Survival and Disease Progression in Patients With Advanced, Recurrent or Metastatic NSCLS Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2006
Completion date
November 30, 2010
Enrollment
889 (actual)
Sites
133

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer